カテゴリ： GlobalData, イギリス, 企業調査

Mylan NV (MYL)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Mylan NV (MYL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9907
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：170
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イギリス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Mylan NV (Mylan) is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics and branded medicines, and consumer healthcare products. It offers pharmaceutical products in multiple forms for various disease conditions related to respiratory and allergy, cardiovascular, dermatology, central nervous system (CNS) and cancer, besides anti-rretrovirals, anaphylaxis products and others. The company also offers active pharmaceutical ingredients (APIs). The company sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The company markets its products in various countries worldwide. Mylan is headquartered in Hatfield, Hertfordshire, the UK.

Mylan NV (MYL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9
Mylan NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10
Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11
Mylan NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12
Mylan NV, Medical Devices Deals, 2012 to YTD 2018 14
Mylan NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15
Mylan NV, Pharmaceuticals & Healthcare, Deal Details 20
Asset Purchase 20
Mylan Acquires TOBI Podhaler and TOBI Solution from Novartis for USD463 Million 20
Mylan to Acquire Marketing Rights to GA Depot from Mapi Pharma 21
Mylan Acquires Global Rights to Cold-EEZE Brand from ProPhase Labs 22
Mylan Acquires Topical Pharmaceutical Business of Renaissance for up to USD1 Billion 23
Teva Pharma May Divest its Assets 24
Mylan Acquires Female Health Care Businesses from Famy Care for USD800 Million 26
Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 28
Mylan to Acquire Rights to Arixtra Injection from Aspen Global 30
Mylan Acquires Rights To Lama Respiratory Compound From Pfizer 31
Mylan Completes Acquisition Of Drug Manufacturing Plant From Unichem For US$30 Million 32
Rottapharm|Madaus Acquires Zyma Brands 33
Meda Acquires OTC Sleep Aid Product, MidNite 34
Mylan Labs To Acquire Manufacturing Unit Of SMS Pharma For US$33 Million 35
Meda Completes Acquisition Of Women’s Health Business From Jazz Pharma For US$95 Million 36
Mylan Acquires Clindamycin Phosphate And Benzoyl Peroxide Gel From Valeant Pharma International 38
Private Equity 39
Ardian May Sell Riemser Pharma for USD494.3 Million 39
Riverside Acquires Euromed from Meda for USD86.7 Million 41
Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 42
Partnerships 44
Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 44
Lupin and Mylan Enter into Partnership Agreement 45
Unimedic Enters into Distribution Agreement with Mylan 46
Mabion Enters into Distribution Agreement with Mylan 47
Pulmatrix Enters into Co-Development Agreement with Mylan 48
AB-Biotics Enters into Distribution Agreement with Mylan 49
Mylan Pharma Enters into Distribution Agreement with Gilead Sciences 50
Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 51
Meda Enters Promotion Agreement With Mission Pharmacal For Elestrin 52
Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences 53
Venus Pharma Enters Into Co-Marketing Agreement With Mylan For Meropenem 54
Pfizer To Enter Into Co-Development Agreement With Mylan For Generic Drugs 55
Agila Specialties Forms Joint Venture With Jamp Pharma 56
Licensing Agreements 57
Mylan Enters into Licensing Agreement with AbbVie 57
Mylan Enters into Licensing Agreement with Fujifilm Kyowa Kirin Biologics 58
Mylan Enters into Licensing Agreement with Revance Therapeutics 59
Mylan Pharma Enters into Licensing Agreement with Otsuka Novel Products for Delamanid 60
Mylan Enters into Licensing Agreement with Genentech and Roche 61
Mylan Enters into Licensing Agreement with Medicines Patent Pool 62
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company for Daclatasvir 63
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 64
Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 65
Gilead Sciences Expands Licensing Agreement with Mylan Labs 67
Mylan Enters into Licensing Agreement with Medicines Patent Pool for HIV Medicines 68
Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 69
Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 70
Gilead Sciences Expands Licensing Agreement with Mylan Labs 71
Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 72
Venus Pharma Enters into Licensing Agreement with Mylan for Meropenem 73
Prosonix Enters Into Licensing Agreement With Mylan For PSX1001 And PSX1050 74
Mylan Enters Into Licensing Agreement With Orion for Stalevo 75
Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 76
Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 78
Equity Offering 79
Abbott Sells stock of Mylan for USD2.29 Billion 79
Meda to Raise USD278.7 Million in Rights Offering 80
Rottapharm Withdraws IPO for USD614.7 Million 82
Debt Offering 83
Mylan Raises USD589.4 Million in Private Offering of 2.125% Notes Due 2025 83
Mylan Raises USD589.3 Million in Public Offering of Notes 84
Mylan Prices Private Placement of 5.2% Notes Due 2048 for USD750 Million 85
Mylan Prices Private Placement of 4.55% Notes Due 2028 for USD750 Million 86
Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 87
Mylan Raises USD796 Million in Private Placement of 1.25% Notes Due 2020 88
Mylan Raises USD796 Million in Private Placement of 3.125% Notes Due 2028 89
Mylan Raises USD1.06 Billion in Private Placement of 2.25% Notes Due 2024 90
Mylan Raises USD531 Million in Private Placement of Floating Rate Notes Due 2018 91
Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 92
Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 93
Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 94
Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 95
Mylan Raises USD500 Million in Private Placement 3.75% Notes Due 2020 96
Mylan Raises USD500 Million in Private Placement 3% Notes Due 2018 97
Mylan Completes Public Offering Of Notes Due 2043 For US$500 Million 98
Mylan Completes Public Offering Of Notes Due 2016 For US$500 Million 100
Mylan Completes Public Offering Of Notes Due 2023 For US$500 Million 102
Mylan Completes Public Offering Of Notes Due 2019 For US$500 Million 104
Mylan Completes Private Placement Of Notes Due 2018 For US$650 Million 105
Mylan Completes Private Placement Of Notes Due 2016 For US$500 Million 106
Meda Prices Public Offering Of Notes Due 2016 For US$62 Million 107
Meda Prices Public Offering Of Notes Due 2018 For US$92.4 Million 108
Mylan Completes Private Placement Of Notes Due 2023 For US$750 Million 109
Asset Transactions 110
Recordati Acquires Rights to Cystagon from Mylan 110
Mylan Labs May Sell Manufacturing Facility 111
Acquisition 112
Mylan Acquires Meda for USD9.42 Billion 112
Mylan Acquires Meda for USD9.9 Billion 114
Teva Pharma, Mylan May Acquire Teut|Pfizer 116
Meda Acquires Rottapharm from Fidim for USD3 Billion 118
Fidim Acquires Rottapharm Biotech from Rottapharm 119
Meda Acquires ZpearPoint, Dental Products Provider 120
Mylan Completes Acquisition Of Agila Specialties From Strides Arcolab For Up To US$1.75 Billion 121
Mylan Rumored To Acquire Bafna Pharma 124
Meda Completes Acquisition Of Acton Pharma For Up To US$200 Million 125
Renaissance Acquisition Acquires DPT Labs, Contract Manufacturing Company 127
Mylan NV – Key Competitors 128
Mylan NV – Key Employees 129
Mylan NV – Locations And Subsidiaries 130
Head Office 130
Other Locations & Subsidiaries 130
Recent Developments 137
Financial Announcements 137
Sep 30, 2018: Mylan Reports Third Quarter 2018 Results and Reaffirms 2018 Guidance 137
Aug 08, 2018: Mylan reports second quarter 2018 results and updates 2018 guidance 142
May 09, 2018: Mylan Reports First Quarter 2018 Results and Reaffirms 2018 Guidance 146
Feb 28, 2018: Mylan Reports Full Year and Fourth Quarter 2017 Results and Provides 2018 Guidance 148
Nov 06, 2017: Mylan Reports Third Quarter 2017 Results and Updates 2017 Guidance 150
Aug 09, 2017: Mylan Reports Second Quarter 2017 Results and Updates 2017 Guidance 152
May 10, 2017: Mylan Reports First Quarter 2017 Results 156
Mar 01, 2017: Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance 158
Corporate Communications 160
May 14, 2018: Mylan and West Virginia University Join Forces to Inspire West Virginia Youth Through STEM-CARE 160
Feb 26, 2018: 16-Year Veteran Director Wendy Cameron to Retire from Mylan Board after 2018 AGM 162
Nov 10, 2017: Mylan Announces Voluntary Delisting from the Tel Aviv Stock Exchange 163
Sep 13, 2017: Mylan Names Dennis Zeleny as Chief Human Relations Officer 164
May 01, 2017: Mylan Nominates Sjoerd Vollebregt for Election to Board of Directors 165
Mar 28, 2017: Mylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer 166
Legal and Regulatory 167
Jun 28, 2018: Mylan Statement: Morgantown Operations 167
Nov 06, 2017: Phosphagenics Mylan Arbitration Hearing Concluded 168
Oct 31, 2017: Mylan Provides Statement in Response to Announcement of Proposed Amendments to Civil Complaint 169
Appendix 170
Methodology 170
About GlobalData 170
Contact Us 170
Disclaimer 170

List of Tables
Mylan NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9
Mylan NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10
Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11
Mylan NV, Deals By Therapy Area, 2012 to YTD 2018 12
Mylan NV, Medical Devices Deals, 2012 to YTD 2018 14
Mylan NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15
Mylan Acquires TOBI Podhaler and TOBI Solution from Novartis for USD463 Million 20
Mylan to Acquire Marketing Rights to GA Depot from Mapi Pharma 21
Mylan Acquires Global Rights to Cold-EEZE Brand from ProPhase Labs 22
Mylan Acquires Topical Pharmaceutical Business of Renaissance for up to USD1 Billion 23
Teva Pharma May Divest its Assets 24
Mylan Acquires Female Health Care Businesses from Famy Care for USD800 Million 26
Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 28
Mylan to Acquire Rights to Arixtra Injection from Aspen Global 30
Mylan Acquires Rights To Lama Respiratory Compound From Pfizer 31
Mylan Completes Acquisition Of Drug Manufacturing Plant From Unichem For US$30 Million 32
Rottapharm|Madaus Acquires Zyma Brands 33
Meda Acquires OTC Sleep Aid Product, MidNite 34
Mylan Labs To Acquire Manufacturing Unit Of SMS Pharma For US$33 Million 35
Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For US$95 Million 36
Mylan Acquires Clindamycin Phosphate And Benzoyl Peroxide Gel From Valeant Pharma International 38
Ardian May Sell Riemser Pharma for USD494.3 Million 39
Riverside Acquires Euromed from Meda for USD86.7 Million 41
Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 42
Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 44
Lupin and Mylan Enter into Partnership Agreement 45
Unimedic Enters into Distribution Agreement with Mylan 46
Mabion Enters into Distribution Agreement with Mylan 47
Pulmatrix Enters into Co-Development Agreement with Mylan 48
AB-Biotics Enters into Distribution Agreement with Mylan 49
Mylan Pharma Enters into Distribution Agreement with Gilead Sciences 50
Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 51
Meda Enters Promotion Agreement With Mission Pharmacal For Elestrin 52
Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences 53
Venus Pharma Enters Into Co-Marketing Agreement With Mylan For Meropenem 54
Pfizer To Enter Into Co-Development Agreement With Mylan For Generic Drugs 55
Agila Specialties Forms Joint Venture With Jamp Pharma 56
Mylan Enters into Licensing Agreement with AbbVie 57
Mylan Enters into Licensing Agreement with Fujifilm Kyowa Kirin Biologics 58
Mylan Enters into Licensing Agreement with Revance Therapeutics 59
Mylan Pharma Enters into Licensing Agreement with Otsuka Novel Products for Delamanid 60
Mylan Enters into Licensing Agreement with Genentech and Roche 61
Mylan Enters into Licensing Agreement with Medicines Patent Pool 62
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company for Daclatasvir 63
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 64
Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 65
Gilead Sciences Expands Licensing Agreement with Mylan Labs 67
Mylan Enters into Licensing Agreement with Medicines Patent Pool for HIV Medicines 68
Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 69
Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 70
Gilead Sciences Expands Licensing Agreement with Mylan Labs 71
Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 72
Venus Pharma Enters into Licensing Agreement with Mylan for Meropenem 73
Prosonix Enters Into Licensing Agreement With Mylan For PSX1001 And PSX1050 74
Mylan Enters Into Licensing Agreement With Orion for Stalevo 75
Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 76
Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 78
Abbott Sells stock of Mylan for USD2.29 Billion 79
Meda to Raise USD278.7 Million in Rights Offering 80
Rottapharm Withdraws IPO for USD614.7 Million 82
Mylan Raises USD589.4 Million in Private Offering of 2.125% Notes Due 2025 83
Mylan Raises USD589.3 Million in Public Offering of Notes 84
Mylan Prices Private Placement of 5.2% Notes Due 2048 for USD750 Million 85
Mylan Prices Private Placement of 4.55% Notes Due 2028 for USD750 Million 86
Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 87
Mylan Raises USD796 Million in Private Placement of 1.25% Notes Due 2020 88
Mylan Raises USD796 Million in Private Placement of 3.125% Notes Due 2028 89
Mylan Raises USD1.06 Billion in Private Placement of 2.25% Notes Due 2024 90
Mylan Raises USD531 Million in Private Placement of Floating Rate Notes Due 2018 91
Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 92
Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 93
Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 94
Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 95
Mylan Raises USD500 Million in Private Placement 3.75% Notes Due 2020 96
Mylan Raises USD500 Million in Private Placement 3% Notes Due 2018 97
Mylan Completes Public Offering Of Notes Due 2043 For US$500 Million 98
Mylan Completes Public Offering Of Notes Due 2016 For US$500 Million 100
Mylan Completes Public Offering Of Notes Due 2023 For US$500 Million 102
Mylan Completes Public Offering Of Notes Due 2019 For US$500 Million 104
Mylan Completes Private Placement Of Notes Due 2018 For US$650 Million 105
Mylan Completes Private Placement Of Notes Due 2016 For US$500 Million 106
Meda Prices Public Offering Of Notes Due 2016 For US$62 Million 107
Meda Prices Public Offering Of Notes Due 2018 For US$92.4 Million 108
Mylan Completes Private Placement Of Notes Due 2023 For US$750 Million 109
Recordati Acquires Rights to Cystagon from Mylan 110
Mylan Labs May Sell Manufacturing Facility 111
Mylan Acquires Meda for USD9.42 Billion 112
Mylan Acquires Meda for USD9.9 Billion 114
Teva Pharma, Mylan May Acquire Teut|Pfizer 116
Meda Acquires Rottapharm from Fidim for USD3 Billion 118
Fidim Acquires Rottapharm Biotech from Rottapharm 119
Meda Acquires ZpearPoint, Dental Products Provider 120
Mylan Completes Acquisition Of Agila Specialties From Strides Arcolab For Up To US$1.75 Billion 121
Mylan Rumored To Acquire Bafna Pharma 124
Meda Completes Acquisition Of Acton Pharma For Up To US$200 Million 125
Renaissance Acquisition Acquires DPT Labs, Contract Manufacturing Company 127
Mylan NV, Key Competitors 128
Mylan NV, Key Employees 129
Mylan NV, Other Locations 130
Mylan NV, Subsidiaries 131

List of Figures
Mylan NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Mylan NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9
Mylan NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 10
Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11
Mylan NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12
Mylan NV, Medical Devices Deals, 2012 to YTD 2018 14

★海外企業調査レポート[Mylan NV (MYL)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Cooperativa Muratori & Cementisti C.M.C di Ravenna：企業の戦略・SWOT・財務分析
    Cooperativa Muratori & Cementisti C.M.C di Ravenna - Strategy, SWOT and Corporate Finance Report Summary Cooperativa Muratori & Cementisti C.M.C di Ravenna - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's struct …
  • LBT Innovations Limited (LBT)-医療機器分野：企業M&A・提携分析
    Summary LBT Innovations Limited (LBT) is a medical device company that designs, develops and commercializes various products and automation technologies for the preparation and analysis of microbiology culture specimens, and microbiology and diagnostic laboratory services. It offers MicroStreak tech …
  • Lanxess AG：企業の戦略・SWOT・財務情報
    Lanxess AG - Strategy, SWOT and Corporate Finance Report Summary Lanxess AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Banco Comercial Portugues SA：企業の戦略・SWOT・財務分析
    Banco Comercial Portugues SA - Strategy, SWOT and Corporate Finance Report Summary Banco Comercial Portugues SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Bloomberg L.P.：企業の戦略・SWOT・財務分析
    Bloomberg L.P. - Strategy, SWOT and Corporate Finance Report Summary Bloomberg L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • State Atomic Energy Corporation Rosatom：企業の戦略的SWOT分析
    State Atomic Energy Corporation Rosatom - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Anthem Inc (ANTM)：企業の財務・戦略的SWOT分析
    Anthem Inc (ANTM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • ABPA Holdings Ltd：企業の戦略的SWOT分析
    ABPA Holdings Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Jiangsu Jiuding New Material Co., Ltd. (002201)：企業の財務・戦略的SWOT分析
    Jiangsu Jiuding New Material Co., Ltd. (002201) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • PT Dian Swastatika Sentosa Tbk (DSSA)：企業の財務・戦略的SWOT分析
    PT Dian Swastatika Sentosa Tbk (DSSA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Bio-Gate Ag (BIG1)：医療機器：M&Aディール及び事業提携情報
    Summary Bio-Gate AG (Bio-Gate) is a medical technology company that develops, manufactures and markets antimicrobial products based on unique silver technologies. Its product portfolio includes antimicrobial plasma coating and additives, among others. The company also provides services such as produ …
  • Apollo Education Group, Inc.：企業の戦略・SWOT・財務分析
    Apollo Education Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Apollo Education Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • SK Bioland Co Ltd：企業の戦略・SWOT・財務分析
    SK Bioland Co Ltd - Strategy, SWOT and Corporate Finance Report Summary SK Bioland Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Bank Sinopac：企業の戦略・SWOT・財務分析
    Bank Sinopac - Strategy, SWOT and Corporate Finance Report Summary Bank Sinopac - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Dana Petroleum Ltd：企業の戦略的SWOT分析
    Dana Petroleum Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Atrion Corp (ATRI)：企業の財務・戦略的SWOT分析
    Atrion Corp (ATRI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • QRxPharma Ltd：企業の戦略的SWOT分析
    QRxPharma Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • China International Travel Service Corporation Limited：企業の戦略・SWOT・財務分析
    China International Travel Service Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary China International Travel Service Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company' …
  • AnaMar AB-医療機器分野：企業M&A・提携分析
    Summary AnaMar AB (AnaMar), a subsidiary of Koncentra Holding AB, discovers, develops and commercializes therapeutic strategies to treat debilitating inflammation, fibrosis and pain. The company develops drug candidates from several chemical classes that concentrates on the receptors and shows poten …
  • NovoCure Ltd (NVCR)：企業の財務・戦略的SWOT分析
    NovoCure Ltd (NVCR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆